Download PDF
Planta Med 2020; 86(12): 867-875
DOI: 10.1055/a-1178-0852
Biological and Pharmacological Activity
Original Papers

Differential Effects of Components in Artemisia annua Extract on the Induction of Drug-Metabolizing Enzyme Expression Mediated by Nuclear Receptors

Xueli Zhang
School of Pharmaceutical Sciences, Shandong University, Jinan, R. P. China
,
Ran Meng
School of Pharmaceutical Sciences, Shandong University, Jinan, R. P. China
,
Haina Wang
School of Pharmaceutical Sciences, Shandong University, Jinan, R. P. China
,
Jie Xing
School of Pharmaceutical Sciences, Shandong University, Jinan, R. P. China
› Author AffiliationsSupported by: Natural Science Foundation of Shandong Province No. ZR2017MH030
› Further Information
    Permissions and Reprints

Abstract

Artemisia annua tea is a popular dosage form used to treat and prevent malaria in some developing countries. However, repeated drinking leads to an obviously decreased efficacy, which may be related to the induction of metabolizing enzymes by artemisinin. In the present study, the ability of different components in A. annua to activate the pregnane X receptor and constitutive androstane receptor was evaluated by the dual luciferase reporter gene system. The changes in mRNA and protein expression of CYP3A4 and CYP2B6 were determined by quantitative real-time PCR and Western blotting. Results showed that in the pregnane X receptor-mediated CYP3A4 reporter gene system, chrysosplenetin and arteannuin B exhibited a weak induction effect on pregnane X receptor wt, while arteannuin A had a strong induction effect on pregnane X receptor wt and pregnane X receptor 370 and a weak induction effect on pregnane X receptor 163. In the pregnane X receptor-mediated CYP2B6 reporter gene system, arteannuin A had a moderate induction effect on pregnane X receptor wt and pregnane X receptor 379, and a weak induction effect on pregnane X receptor 403, while arteannuin B had a weak induction effect on pregnane X receptor wt and pregnane X receptor 379. Arteannuin A had a strong induction effect on constitutive androstane receptor 3 in constitutive androstane receptor-mediated CYP3A4/2B6 reporter gene systems, while arteannuin B showed a weak induction effect on constitutive androstane receptor 3 in the constitutive androstane receptor-mediated CYP2B6 reporter gene system. The mRNA and protein expressions of CYP3A4 and CYP2B6 were increased when the pregnane X receptor or constitutive androstane receptor was activated. Various components present in A. annua differentially affect the activities of pregnane X receptor isoforms and the constitutive androstane receptor, which indicates the possibility of a drug-drug interaction. This partly explains the decline in efficacy after repeated drinking of A. annua tea.

Key words

arteannuin A - arteannuin B - Artemisia annua - Asteraceae - metabolic drug-drug interactions - CYP3A4/2B6 - PXR/CAR


Publication History

Received: 30 October 2019

Accepted: 05 May 2020

Article published online:
17 June 2020

Georg Thieme Verlag KG
Stuttgart · New York

 

  • References

  • 1 Cowman AF, Healer J, Marapana D, Marsh K. Malaria: biology and disease. Cell 2016; 167: 610-624
    CrossrefPubMedGoogle Scholar
  • 2 White NJ, Pukrittayakamee S, Hien TT, Faiz MA, Mokuolu OA, Dondorp AM. Malaria. Lancet 2014; 383: 723-735
    CrossrefPubMedGoogle Scholar
  • 3 WHO. World malaria report 2018. Available at (Accessed January 4, 2019): https://www.who.int/malaria/publications/world-malaria-report-2018/en/
    PubMedGoogle Scholar
  • 4 Krungkrai J, Krungkrai SR. Antimalarial qinghaosu/artemisinin: The therapy worthy of a Nobel Prize. Asian Pac J Trop Biomed 2016; 6: 371-375
    CrossrefPubMedGoogle Scholar
  • 5 Li Y. Qinghaosu (artemisinin): chemistry and pharmacology. Acta Pharmacol Sin 2012; 33: 1141-1146
    CrossrefPubMedGoogle Scholar
  • 6 WHO. Guidelines for the treatment of malaria Third edition. Available at (Accessed February 26, 2019): https://extranetwhoint/rhl/guidelines/guidelines-treatment-malaria-third-edition
    PubMedGoogle Scholar
  • 7 OʼConnell KA, Gatakaa H, Poyer S, Njogu J, Evance I, Munroe E, Solomon T, Goodman C, Hanson K, Zinsou C, Akulayi L, Raharinjatovo J, Arogundade E, Buyungo P, Mpasela F, Adjibabi CB, Agbango JA, Ramarosandratana BF, Coker B, Rubahika D, Hamainza B, Chapman S, Shewchuk T, Chavasse D. Got ACTs? Availability, price, market share and provider knowledge of anti-malarial medicines in public and private sector outlets in six malaria-endemic countries. Malar J 2011; 10: 326
    CrossrefPubMedGoogle Scholar
  • 8 Ferreira JFS, Benedito VA, Sandhu D, Marchese JA, Liu S. Seasonal and differential sesquiterpene accumulation in Artemisia annua suggest selection based on both artemisinin and dihydroartemisinic acid may increase artemisinin in planta . Front Plant Sci 2018; 9: 1096
    CrossrefPubMedGoogle Scholar
  • 9 de Ridder S, van der Kooy F, Verpoorte R. Artemisia annua as a self-reliant treatment for malaria in developing countries. J Ethnopharmacol 2008; 120: 302-314
    CrossrefPubMedGoogle Scholar
  • 10 Willcox M. Artemisia species: from traditional medicines to modern antimalarials – and back again. J Altern Complement Med 2009; 15: 101-109
    CrossrefPubMedGoogle Scholar
  • 11 Liu CX. Discovery and development of artemisinin and related compounds. Chin Herb Med 2017; 9: 101-114
    CrossrefPubMedGoogle Scholar
  • 12 van der Kooy F, Sullivan SE. The complexity of medicinal plants: the traditional Artemisia annua formulation, current status and future perspectives. J Ethnopharmacol 2013; 150: 1-13
    CrossrefPubMedGoogle Scholar
  • 13 Suberu JO, Gorka AP, Jacobs L, Roepe PD, Sullivan N, Barker GC, Lapkin AA. Anti-plasmodial polyvalent interactions in Artemisia annua L. aqueous extract – possible synergistic and resistance mechanisms. PLoS One 2013; 8: e80790
    CrossrefPubMedGoogle Scholar
  • 14 Ferreira JF, Luthria DL, Sasaki T, Heyerick A. Flavonoids from Artemisia annua L. as antioxidants and their potential synergism with artemisinin against malaria and cancer. Molecules 2010; 15: 3135-3170
    CrossrefPubMedGoogle Scholar
  • 15 Rasoanaivo P, Wright CW, Willcox ML, Gilbert B. Whole plant extracts versus single compounds for the treatment of malaria: synergy and positive interactions. Malar J 2011; 10 (Suppl. 01) S4
    CrossrefPubMedGoogle Scholar
  • 16 Mouton J, Jansen O, Frederich M, van der Kooy F. Is artemisinin the only antiplasmodial compound in the Artemisia annua tea infusion? An in vitro study. Planta Med 2013; 79: 468-470
    Article in Thieme ConnectPubMedGoogle Scholar
  • 17 Blanke CH, Naisabha GB, Balema MB, Mbaruku GM, Heide L, Muller MS. Herba Artemisiae annuae tea preparation compared to sulfadoxine-pyrimethamine in the treatment of uncomplicated falciparum malaria in adults: a randomized double-blind clinical trial. Trop Doct 2008; 38: 113-116
    CrossrefPubMedGoogle Scholar
  • 18 Wanwimolruk S, Phopin K, Prachayasittikul V. Cytochrome P450 enzyme mediated herbal drug interactions (Part 2). EXCLI J 2014; 13: 869-896
    PubMedGoogle Scholar
  • 19 Wanwimolruk S, Prachayasittikul V. Cytochrome P450 enzyme mediated herbal drug interactions (Part 1). EXCLI J 2014; 13: 347-391
    PubMedGoogle Scholar
  • 20 Tirona RG, Bailey DG. Herbal product-drug interactions mediated by induction. Br J Clin Pharmacol 2006; 61: 677-681
    CrossrefPubMedGoogle Scholar
  • 21 Durr D, Stieger B, Kullak-Ublick GA, Rentsch KM, Steinert HC, Meier PJ, Fattinger K. St Johnʼs Wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4. Clin Pharmacol Ther 2000; 68: 598-604
    CrossrefPubMedGoogle Scholar
  • 22 Leucuta SE, Vlase L. Pharmacokinetics and metabolic drug interactions. Curr Clin Pharmacol 2006; 1: 5-20
    CrossrefPubMedGoogle Scholar
  • 23 Svensson USH, Ashton M. Identification of the human cytochrome P450 enzymes involved in the in vitro metabolism of artemisinin. Brit J Clin Pharmaco 1999; 48: 528-535
    CrossrefPubMedGoogle Scholar
  • 24 Gao J, Xie W. Targeting xenobiotic receptors PXR and CAR for metabolic diseases. Trends Pharmacol Sci 2012; 33: 552-558
    CrossrefPubMedGoogle Scholar
  • 25 Faucette SR, Sueyoshi T, Smith CM, Negishi M, Lecluyse EL, Wang H. Differential regulation of hepatic CYP2B6 and CYP3A4 genes by constitutive androstane receptor but not pregnane X receptor. J Pharmacol Exp Ther 2006; 317: 1200-1209
    CrossrefPubMedGoogle Scholar
  • 26 Wang X, Bai KH, Sun K, Zhang SQ. Inductive effects of artemisinin-based antimalarials on nuclear receptor CAR and CYP2B in rats liver. Chin Rem Clin 2010; 10: 849-851
    PubMedGoogle Scholar
  • 27 Burk O, Arnold KA, Nussler AK, Schaeffeler E, Efimova E, Avery BA, Avery MA, Fromm MF, Eichelbaum M. Antimalarial artemisinin drugs induce cytochrome P450 and MDR1 expression by activation of xenosensors pregnane X receptor and constitutive androstane receptor. Mol Pharmacol 2005; 67: 1954-1965
    CrossrefPubMedGoogle Scholar
  • 28 Zang M, Zhao L, Zhu F, Li X, Yang A, Xing J. Effect of CAR polymorphism on the pharmacokinetics of artemisinin in healthy Chinese subjects. Drug Metab Pharmacokinet 2015; 30: 123-126
    CrossrefPubMedGoogle Scholar
  • 29 Agrawal V, Choi JH, Giacomini KM, Miller WL. Substrate-specific modulation of CYP3A4 activity by genetic variants of cytochrome P450 oxidoreductase. Pharmacogenet Genomics 2010; 20: 611-618
    CrossrefPubMedGoogle Scholar
  • 30 Brewer CT, Chen T. PXR variants: the impact on drug metabolism and therapeutic responses. Acta Pharm Sin B 2016; 6: 441-449
    CrossrefPubMedGoogle Scholar
  • 31 Luo G, Cunningham M, Kim S, Burn T, Lin J, Sinz M, Hamilton G, Rizzo C, Jolley S, Gilbert D, Downey A, Mudra D, Graham R, Carroll K, Xie J, Madan A, Parkinson A, Christ D, Selling B, LeCluyse E, Gan LS. CYP3A4 induction by drugs: correlation between a pregnane X receptor reporter gene assay and CYP3A4 expression in human hepatocytes. Drug Metab Dispos 2002; 30: 795-804
    CrossrefPubMedGoogle Scholar
  • 32 Cai TY, Zhang YR, Ji JB, Xing J. Investigation of the component in Artemisia annua L. leading to enhanced antiplasmodial potency of artemisinin via regulation of its metabolism. J Ethnopharmacol 2017; 207: 86-91
    CrossrefPubMedGoogle Scholar
  • 33 Pal D, Mitra AK. MDR- and CYP3A4-mediated drug-drug interactions. J Neuroimmune Pharmacol 2006; 1: 323-339
    CrossrefPubMedGoogle Scholar
  • 34 Lemaire G, de Sousa G, Rahmani R. A PXR reporter gene assay in a stable cell culture system: CYP3A4 and CYP2B6 induction by pesticides. Biochem Pharmacol 2004; 68: 2347-2358
    CrossrefPubMedGoogle Scholar
  • 35 Na DH, Ji HY, Park EJ, Kim MS, Liu KH, Lee HS. Evaluation of metabolism-mediated herb-drug interactions. Arch Pharm Res 2011; 34: 1829-1842
    CrossrefPubMedGoogle Scholar
  • 36 Auerbach SS, Stoner MA, Su S, Omiecinski CJ. Retinoid X receptor-alpha-dependent transactivation by a naturally occurring structural variant of human constitutive androstane receptor (NR1I3). Mol Pharmacol 2005; 68: 1239-1253
    CrossrefPubMedGoogle Scholar
  • 37 Pinne M, Ponce E, Raucy JL. Transactivation assays to assess canine and Rodent Pregnane X Receptor (PXR) and Constitutive Androstane Receptor (CAR) Activation. PLoS One 2016; 11: e0164642
    CrossrefPubMedGoogle Scholar
  • 38 Tanaka E. Clinically important pharmacokinetic drug-drug interactions: role of cytochrome P450 enzymes. J Clin Pharm Ther 1998; 23: 403-416
    CrossrefPubMedGoogle Scholar
  • 39 Prakash C, Zuniga B, Song CS, Jiang S, Cropper J, Park S, Chatterjee B. Nuclear receptors in drug metabolism, drug response and drug interactions. Nucl Receptor Res 2015; 2: 101178
    CrossrefPubMedGoogle Scholar
  • 40 Lamba JK, Lin YS, Schuetz EG, Thummel KE. Genetic contribution to variable human CYP3A-mediated metabolism. Adv Drug Deliv Rev 2012; 64: 256-269
    CrossrefPubMedGoogle Scholar
  • 41 Lim YP, Liu CH, Shyu LJ, Huang JD. Functional characterization of a novel polymorphism of pregnane X receptor, Q158K, in Chinese subjects. Pharmacogenet Genomics 2005; 15: 337-341
    CrossrefPubMedGoogle Scholar
  • 42 Hustert E, Zibat A, Presecan-Siedel E, Eiselt R, Mueller R, Fuss C, Brehm I, Brinkmann U, Eichelbaum M, Wojnowski L, Burk O. Natural protein variants of pregnane X receptor with altered transactivation activity toward CYP3A4. Drug Metab Dispos 2001; 29: 1454-1459
    PubMedGoogle Scholar
  • 43 Lamba J, Lamba V, Schuetz E. Genetic variants of PXR (NR1I2) and CAR (NR1I3) and their implications in drug metabolism and pharmacogenetics. Curr Drug Metab 2005; 6: 369-383
    CrossrefPubMedGoogle Scholar
  • 44 Bosch TM, Deenen M, Pruntel R, Smits PH, Schellens JH, Beijnen JH, Meijerman I. Screening for polymorphisms in the PXR gene in a Dutch population. Eur J Clin Pharmacol 2006; 62: 395-399
    CrossrefPubMedGoogle Scholar
  • 45 Koyano S, Kurose K, Saito Y, Ozawa S, Hasegawa R, Komamura K, Ueno K, Kamakura S, Kitakaze M, Nakajima T, Matsumoto K, Akasawa A, Saito H, Sawada J. Functional characterization of four naturally occurring variants of human pregnane X receptor (PXR): one variant causes dramatic loss of both DNA binding activity and the transactivation of the CYP3A4 promoter/enhancer region. Drug Metab Dispos 2004; 32: 149-154
    CrossrefPubMedGoogle Scholar
  • 46 Oladimeji PO, Chen T. PXR: more than just a master xenobiotic receptor. Mol Pharmacol 2018; 93: 119-127
    CrossrefPubMedGoogle Scholar
  • 47 Lim YP, Huang JD. Pregnane X receptor polymorphism affects CYP3A4 induction via a ligand-dependent interaction with steroid receptor coactivator-1. Pharmacogenet Genomics 2007; 17: 369-382
    CrossrefPubMedGoogle Scholar
  • 48 Rana M, Devi S, Gourinath S, Goswami R, Tyagi RK. A comprehensive analysis and functional characterization of naturally occurring non-synonymous variants of nuclear receptor PXR. Biochim Biophys Acta 2016; 1859: 1183-1197
    CrossrefPubMedGoogle Scholar